Sanofi (SNY)

43.55
0.60 1.36
NYSE : Health Technology
Prev Close 44.15
Open 43.62
Day Low/High 43.55 / 43.98
52 Wk Low/High 37.43 / 50.65
Volume 1.59M
Avg Volume 2.06M
Exchange NYSE
Shares Outstanding 2.58B
Market Cap 109.72B
EPS 1.70
P/E Ratio 23.60
Div & Yield 1.20 (2.85%)

Latest News

Cablivi™ (caplacizumab) Approved In Europe For Adults With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

Cablivi™ (caplacizumab) Approved In Europe For Adults With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

- First therapeutic approved for the treatment of aTTP, a rare blood-clotting disorder

Elon Musk Has Lost It and Must Consider Bringing In Facebook's Sheryl Sandberg

Elon Musk Has Lost It and Must Consider Bringing In Facebook's Sheryl Sandberg

Nvidia, nvidia, NVIDIA. In non-Nvidia news, the market faces some serious threats in the back half of 2018. And hey, about Elon Musk's latest interview ...

Q2 2018 Performance Positions Sanofi For New Growth Phase

Q2 2018 Performance Positions Sanofi For New Growth Phase

PARIS, July 31, 2018 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q2 2018 Change Change at CER H1 2018 Change Change at CER IFRS net sales reported €8,176m -5.

Sanofi Ships First Flu Vaccines For 2018-2019 Season

Sanofi Ships First Flu Vaccines For 2018-2019 Season

Nearly 70 million doses to be manufactured this season

New Insights Revealed In National Survey Show More Advances Are Needed For The Type 1 Diabetes Community

New Insights Revealed In National Survey Show More Advances Are Needed For The Type 1 Diabetes Community

Endocrinologists and Adults with Type 1 Diabetes Struggle to Keep Blood Sugar within Recommended Range Yet Remain Hopeful and Optimistic About the Future of Disease Management

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CFBK, CLDT, SNY, VET Downgrades: ADNT, AOI, BVN Initiations: AMMA Read on to get TheStreet Quant Ratings' detailed report:

New England Journal Of Medicine Publishes Final Results From Innovative Phase 2 Study Showing Vaccines Can Reduce Rate Of Sustained TB Infections In Adolescents At High Risk

New England Journal Of Medicine Publishes Final Results From Innovative Phase 2 Study Showing Vaccines Can Reduce Rate Of Sustained TB Infections In Adolescents At High Risk

Trial offers hope for new revaccination strategies with Bacille Calmette-Guerin (BCG) against Tuberculosis, the world's leading infectious disease killer

Sanofi To Further Accelerate Its Scientific Presence With The Opening Of A Global R&D Operations Hub In Chengdu, China

Sanofi To Further Accelerate Its Scientific Presence With The Opening Of A Global R&D Operations Hub In Chengdu, China

- Company invests €66 million in Chengdu, Sichuan province, China

Sanofi Presents Results From The First Head-to-head Study Comparing Toujeo® To Insulin Degludec

Sanofi Presents Results From The First Head-to-head Study Comparing Toujeo® To Insulin Degludec

- Toujeo (insulin glargine injection 300 Units/mL) met primary endpoint in lowering blood sugar levels and was non-inferior to insulin degludec in adults with type 2 diabetes not previously on insulin

Drug Pricing Turns to Insulin as Politicians, AMA and Docs Look to Pharma

Drug Pricing Turns to Insulin as Politicians, AMA and Docs Look to Pharma

Insulin has been around since 1921. But there is no generic drug and four companies control the market. Now politicians, the AMA and patient groups are looking for lower prices.

Canadian Employers Underestimate The Proportion Of Their Workforce With A Chronic Condition And Its Impact

Canadian Employers Underestimate The Proportion Of Their Workforce With A Chronic Condition And Its Impact

Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Three-quarters of employers are worried about the impact of unmanaged chronic disease Two-thirds (66%) of Canadian employees would consent to receive personalized information based on their own benefits claims...

Sanofi, Merck and J&J Tout Lower Drug Prices

Sanofi, Merck and J&J Tout Lower Drug Prices

While a handful of drug companies say their average net prices have dropped, FDA Commissioner Scott Gottlieb announces a plan to encourage drug competition in the face of monopolies.

Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs

Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs

Senior vice president Enrique Conterno says the Type-2 diabetes treatment is part of the fast-growing glucagon-like peptide-1 receptor agonists.

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

The tough news keeps coming at the generic drug company, which announced last week it was considering putting itself up for sale. Now the Justice Department wants a chat.

FDA Accepts For Review Supplemental Biologics License Application For 0.5 ML Dose Of Fluzone® Quadrivalent (Influenza Vaccine) In Children 6-35 Months Of Age

- If approved, health care professionals will be able to use the same 0.5 mL dose of Fluzone Quadrivalent vaccine with all patients ages 6 months and older for whom flu vaccination is recommended - which may provide more flexibility and convenience to immunizers.

Closing Bell: LIVE MARKETS BLOG

Closing Bell: LIVE MARKETS BLOG

Markets closed near session highs Monday.

Philippine FDA Says Sanofi of Knew of Vaccine's Dangers in 2015

Philippine FDA Says Sanofi of Knew of Vaccine's Dangers in 2015

The Philippine government says Sanofi knew that the vaccine should not have been given to people who have never had dengue fever.

Citi Will Refund $335 Million in Card Charges: LIVE MARKETS BLOG

Citi Will Refund $335 Million in Card Charges: LIVE MARKETS BLOG

The charges were related to an interest-rate problem.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: OMC, WMS Downgrades: ALSK, ATV, BP, CARB, CMP, CRL, DAN, FRT, SNY, VNO, WU, ZIXI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget

The Creating and Restoring Equal Access to Equivalent Samples Act, a measure aimed at making it easier for generic drug companies to research name brand drugs, was left out of the final budget.

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

A steeper fall might cause both buyers and sellers to re-think potential deals, but so far that doesn't seem to be the case yet.

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

A week after unveiling an $11.6-billion deal for Bioverativ, Sanofi said it was spending another $4.8 billion to acquire Belgian biotech firm Ablynx.

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

U.S. stock futures trade lower, Donald Trump's national security advisers look at building a 5G network, and France's Sanofi buys Belgian biotech Ablynx.

Nationalized 5G and Everything Else You Need to Know Before You Trade Monday

Nationalized 5G and Everything Else You Need to Know Before You Trade Monday

As the Trump administration reportedly considers government controlled 5G, investors prepare for a hectic week of earnings.

Tax Reform's Impact on the Economy

Tax Reform's Impact on the Economy

Consumer spending should be more than solid given wage increases.

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Here's what you need to know now for Monday, Jan. 22.

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

With a boost from the NFL and its own IPO, Quanterix hopes to engage biopharma companies to use its platform to speed safety and efficacy results for neurology, oncology and inflammation pipelines.

Allergan and Energy Stocks Have Big Days

A flurry of high-priced merger-and-acquisition activity explains the move in Allergan.

TheStreet Quant Rating: B (Buy)